Imclone have just announced their 1st Qtr 2004 earnings . Revenues have rocketed to 109.6 million USD with a net of 62.7 million USD . All this on the sales of their new drug for metastatic colorectal cancer ,erbitux . This is a marginal drug at best , with response time in combination with chemo of 5.7 months before disease progression and 1.5 months as a stand alone treatment .
That looks ordinary compared to what Solbec were seeing in their special access patients .
- Forums
- ASX - By Stock
- earnings
SBP
solbec pharmaceuticals limited
Imclone have just announced their 1st Qtr 2004 earnings ....
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
AFP
AFT PHARMACEUTICALS LIMITED
Hartley Atkinson, CEO & Founder
Hartley Atkinson
CEO & Founder
Previous Video
Next Video
SPONSORED BY The Market Online